Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Imprimir: 0278-940X
ISSN On-line: 1943-619X

Volumes:
Volume 47, 2019 Volume 46, 2018 Volume 45, 2017 Volume 44, 2016 Volume 43, 2015 Volume 42, 2014 Volume 41, 2013 Volume 40, 2012 Volume 39, 2011 Volume 38, 2010 Volume 37, 2009 Volume 36, 2008 Volume 35, 2007 Volume 34, 2006 Volume 33, 2005 Volume 32, 2004 Volume 31, 2003 Volume 30, 2002 Volume 29, 2001 Volume 28, 2000 Volume 27, 1999 Volume 26, 1998 Volume 25, 1997 Volume 24, 1996 Volume 23, 1995

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.2016016141
pages 347-369

Stealth Engineering for In Vivo Drug Delivery Systems

Ankita Mohapatra
Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN 38152
Bashir I. Morshed
Department of Electrical and Computer Engineering, University of Memphis, Memphis, TN 38152
Warren O. Haggard
Chair Excellence Associate Dean, Department of Biomedical Engineering, University of Memphis, Memphis, TN 38152
Richard A. Smith
Department of Orthopedic Surgery & Biomedical Engineering, University of Tennessee Campbell Clinic, Memphis, TN 38163

RESUMO

In generic terms, a drug delivery substrate (DDS) can be described as a vehicle to transport drug to the point of interest. A DDS that would ideally have the capability to control drug dosage and achieve target specificity, localization, and higher therapeutic efficacy has been pursued as a holy grail in pharmaceutical research. Over the years, diverse classes, structures, and modifications of DDS have been proposed to achieve this aim. One of its major deterrents, however, is rapid elimination of drug by the immune system before intended functionality. Stealth engineering is broadly defined as a method of designing a drug carrier to minimize or delay opsonization until the encapsulated drug is delivered to the intended target. Stealth-engineered DDS has been successful in extending drug circulation lifetime from a few minutes to several days. Currently, this field of research has made much progress since its initiation in 1960s with liposomes to DNA boxes. Activity has also benefited several areas of medicine, where it has been applied in cancer, gene therapy, bone regrowth, and infection treatment. This review covers the progress of some types of DDS that have been published and indexed in major databases (including ScienceDirect, PubMed, and Google Scholar) in the scientific literature.